OTCMKTS:ASPCF Acerus Pharmaceuticals - ASPCF Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Acerus Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. $0.22 0.00 (0.00%) (As of 03/17/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.22▼$0.2250-Day Range$0.22▼$0.3752-Week Range$0.22▼$8.16VolumeN/AAverage Volume1,500 shsMarket Capitalization$1.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsHeadlinesShort Interest About Acerus Pharmaceuticals (OTCMKTS:ASPCF) StockAcerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men's health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.Read More Receive ASPCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ASPCF Stock News HeadlinesMarch 14, 2023 | finance.yahoo.comAcerus Announces Commencement of Court-Approved Sale and Investment Solicitation ProcessJanuary 16, 2023 | theglobeandmail.comAcerus Pharmaceuticals: Top 10 Undervalued Nano Cap Stocks on TSX (ASP)March 20, 2023 | Investing Daily (Ad)Check Out This 6-Year Win StreakDespite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. November 15, 2022 | finance.yahoo.comAcerus Reports Third Quarter 2022 Financial ResultsOctober 3, 2022 | finance.yahoo.comAcerus Announces Amendment to Promissory Note Due to Former Serenity ShareholdersSeptember 21, 2022 | marketwatch.comAcerus Pharmaceuticals to Initiate Strategic Review of OperationsSeptember 21, 2022 | finance.yahoo.comAcerus Announces Initiation of Strategic ReviewAugust 23, 2022 | seekingalpha.comAcerus Pharmaceuticals CFO resigns effective November 20, 2022March 20, 2023 | Investing Daily (Ad)Check Out This 6-Year Win StreakDespite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. August 14, 2022 | seekingalpha.comAcerus Pharmaceuticals Corporation (ASPCF) CEO Edward Gudaitis on Q2 2022 Results - Earnings Call TranscriptAugust 5, 2022 | finance.yahoo.comAcerus Announces Amendments to Loan Facility and Promissory Note Due to Former Serenity ShareholdersJune 27, 2022 | finance.yahoo.comAcerus Announces Voting Results for the 2022 Annual MeetingJune 24, 2022 | seekingalpha.comAcerus Pharmaceuticals increases loan facility to $37.94MMay 11, 2022 | seekingalpha.comAcerus Pharmaceuticals GAAP EPS of $0.00, revenue of $0.78MMay 5, 2022 | finance.yahoo.comAcerus To Report Q1-2022 Financial Results And Host Investor CallApril 26, 2022 | finance.yahoo.comAcerus Announces Completion of Share ConsolidationApril 19, 2022 | finance.yahoo.comAcerus Announces Share ConsolidationFebruary 28, 2022 | seekingalpha.comAcerus to acquire Florida-based Serenity in cash/stock dealFebruary 28, 2022 | finance.yahoo.comAcerus Announces Definitive Agreement to Acquire Serenity LLC and the Global Rights to Noctiva™See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ASPCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ASPCF Company Calendar Today3/20/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ASPCF CUSIPN/A CIKN/A Webwww.aceruspharma.com Phone(416) 679-0771Fax905-569-1809Employees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,820,000.00 Net Margins-924.33% Pretax Margin-924.33% Return on EquityN/A Return on Assets-74.62% Debt Debt-to-Equity RatioN/A Current Ratio0.67 Quick Ratio0.34 Sales & Book Value Annual Sales$2.12 million Price / Sales0.80 Cash FlowN/A Price / Cash FlowN/A Book Value($3.38) per share Price / Book-0.07Miscellaneous Outstanding Shares7,708,000Free FloatN/AMarket Cap$1.69 million OptionableNot Optionable Beta0.69 Key ExecutivesEdward GudaitisPresident, CEO & Non-Independent DirectorNaveed ManzoorChief Financial OfficerChristopher SorliChief Medical OfficerPhilippe SavardSecretary, Senior Vice President & General CounselChris WittyInvestor Relations ContactKey CompetitorsMallinckrodtOTCMKTS:MNKKQInternational Stem CellOTCMKTS:ISCOScopus BioPharmaNASDAQ:SCPSSciSparcNASDAQ:SPRCAltamira TherapeuticsNASDAQ:CYTOView All Competitors ASPCF Stock - Frequently Asked Questions How have ASPCF shares performed in 2023? Acerus Pharmaceuticals' stock was trading at $0.5579 at the beginning of 2023. Since then, ASPCF shares have decreased by 60.6% and is now trading at $0.2199. View the best growth stocks for 2023 here. When did Acerus Pharmaceuticals' stock split? Acerus Pharmaceuticals's stock reverse split on the morning of Friday, April 29th 2022. The 1-200 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What is Acerus Pharmaceuticals' stock symbol? Acerus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ASPCF." How do I buy shares of Acerus Pharmaceuticals? Shares of ASPCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Acerus Pharmaceuticals' stock price today? One share of ASPCF stock can currently be purchased for approximately $0.22. How much money does Acerus Pharmaceuticals make? Acerus Pharmaceuticals (OTCMKTS:ASPCF) has a market capitalization of $1.69 million and generates $2.12 million in revenue each year. The company earns $-33,820,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis. How can I contact Acerus Pharmaceuticals? Acerus Pharmaceuticals' mailing address is 2486 Dunwin Drive, Mississauga A6, L5L 1J9. The official website for the company is www.aceruspharma.com. The company can be reached via phone at (416) 679-0771, via email at ir@aceruspharma.com, or via fax at 905-569-1809. This page (OTCMKTS:ASPCF) was last updated on 3/20/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.